Exclusive: Tencent-Backed WeDoctor Readies Hong Kong IPO
WeDoctor, an online medical services provider backed by Tencent Holdings Ltd., plans to file a prospectus by October for a Hong Kong IPO that it hopes will raise between $700 million and $900 million, Caixin can reveal.
The windfall would value the money-losing tech firm at around $5.5 billion, about the same as a $50 million May funding round.
WeDoctor is just one of many tech companies hoping to capitalize on the disruptions to the traditional health care industry brought by Covid-19.
Although the company has not nailed down its business model, it is pursuing an IPO to take advantage of the high valuations commanded by health care companies right now despite its subdued growth, an insider from one of its cornerstone investors told Caixin.
The person said there was also pressure to go public from limited partners who were early investors in the company and now want to cash out. Caixin granted the person anonymity so they could speak candidly.
According to financial records obtained by Caixin, in the three years from 2016 to 2018, WeDoctor brought in revenue of 437 million yuan, 604 million yuan and 1.2 billion yuan, and took losses of 480 million yuan, 674 million yuan and 818 million yuan. Data provided by company insiders showed in 2019 that the company narrowed its losses and brought in nearly 4 billion yuan, much higher than the 2.8 billion yuan expected at the beginning of the year.
But the company will still be forced to demonstrate it has a viable business model.
Rumors of WeDoctor’s IPO plans have persisted since 2018, when it secured $500 million in financing from AIA Group Ltd., NWS Holdings Ltd. and China Capital Zhongcai Fund Management.
WeDoctor plans to hire CMB International, Citigroup and JPMorgan to underwrite its IPO listing.
Online medical services in China have found it hard to turn a profit because most of their fee income goes to doctors.
But the company could benefit from policy support, after health authorities issued new guidelines (link in Chinese) for China’s medical insurance system that extended coverage to internet-based medical services during the epidemic.
Zhu Hengpeng, deputy director of the Institute of Economics at the Chinese Academy of Social Sciences, said while the Covid-19 epidemic has accelerated the development of digital medicine and online health care, it was unclear whether those changes would remain long term.
WeDoctor’s predecessor was Guahao.com, an advertising funded app that ranked hospitals and booked appointments — many of which were from the prolific advertisers Putian hospital group.
Revenue grew slowly for the company and was outstripped by growing losses in 2013 and 2014, even before Putian and Baidu were implicated in the 2016 death of a 21-year-old college student named Wei Zexi, who was led by a paid ad on Baidu to a costly and bogus experimental cancer treatment offered by a Putian hospital.
But while Baidu’s digital health ambitions were poisoned for years by the death, Guahao had already rebranded as WeDoctor and was pivoting away from online hospital appointments — which were banned that year by the Beijing Municipal Health Commission — and into telehealth.
WeDoctor obtained $394 million in series D funding that year from Tencent, Fosun Pharma, Goldman Sachs and others.
In China, where medical services are generally low cost, fees for digital health have generally come from existing health budgets, meaning achieving scale has been of little benefit.
But the Covid-19 pandemic has been a boon for tech companies on the prowl to take advantage of the disruption of traditional health services.
Ping An Good Doctor, cornerstone investor in WeDoctor, saw its Hong Kong share price double in the past six months. Alibaba Health, a new pharmaceutical retailer, has seen similar growth.
In the second half of last year, WeDoctor began to establish a health community with multiple provincial and city governments and medical institutions. Through digital platforms, it works with offline institutions, signing contracts with local family doctors and chronic disease management plans.
Contact reporter Flynn Murphy (firstname.lastname@example.org) and editor Michael Bellart (michealbellart @caixin.com)
- MOST POPULAR